

Curriculum Vitae

Richard A. Chazal MD, MACC, FACP, FASE, FAHA

Lee Health Cardiology at Med Plaza One
9800 S. HealthPark Drive, Suite 320
Fort Myers, Florida 33908
(239) 343-6350

Professional Experience:

- 2017 – Present Clinical Associate Professor
Florida State University College of Medicine
- 2012 – Present Medical Director, Heart and Vascular Institute
Lee Health System
- 2012 – Present Courtesy Assistant Professor of Medicine (Cardiology)
University of Florida
- 2012 – 2017 Clinical Assistant Professor of Medicine
Florida State University College of Medicine
- 2010 – Present Consultative and Invasive Cardiology
Lee Health Cardiology at Med Plaza One, Fort Myers, Florida
- 2005 – 2010 Private Practice, Consultative and Invasive Cardiology
The Heart Group, P.L., Fort Myers, Florida
- 1983 – 2005 Private Practice, Consultative and Invasive Cardiology
Southwest Florida Heart Group, Fort Myers, Florida

Education:

- 1981 – 1982 Research Fellow in Echocardiography
Indiana University School of Medicine
- 1980 - 1983 Fellow – Cardiovascular Disease
Indiana University School of Medicine
- 1980 Acting Chief Resident
Tampa General Hospital, Tampa, FL
- 1977 - 1980 Internship and Residency – Internal Medicine
University of South Florida Medical Center, Tampa, Florida
- 1977 University of South Florida, Tampa, Florida – MD
- 1974 University of Florida, Gainesville, Florida – BS, Chemistry

Professional Memberships/Organizations:

- 2018 - Present World Heart Federation Board Member, Geneva, Switzerland
- 2018 - Present Past President, American College of Cardiology
- 2017 - Present ACCEL Editorial Board Member, American College of Cardiology
- 2017 - 2018 Immediate Past President, American College of Cardiology
- 2016 - 2017 President, American College of Cardiology

Professional Memberships/Organizations continued:

2015 - 2016 President-Elect, American College of Cardiology
2014-2020 Trustee, American College of Cardiology
2014 - 2018 Executive Committee, American College of Cardiology
2014 - 2015 Vice President, American College of Cardiology
2013 - 2015 President, AHA Southwest Florida Affiliate
2009-2012 Executive Committee, American College of Cardiology
2009 - 2012 Chair, ACC Budget, Finance and Investment Committee
2009 - 2012 Treasurer, American College of Cardiology
2005 Chair, ACC Board of Governors
2002 - 2005 President, Florida Chapter, American College of Cardiology
2002 - 2005 Governor, American College of Cardiology
2004-2012 Trustee, American College of Cardiology
2004-2006 Executive Committee, American College of Cardiology
Master, American College of Cardiology
Fellow, American College of Cardiology
Fellow, American College of Physicians
Fellow, American Heart Association
Fellow, American Society of Echocardiography
Fellow, The Society for Cardiac Angiography & Interventions
Fellow, European Society of Cardiology
Florida Medical Association
Lee County Medical Association
Sigma Chi Fraternity

Awards/Honors:

2017 Master, American College of Cardiology
2017 Lifetime Achievement Award
Lee County Medical Society
2015 Outstanding Community Teaching Award
Family Medicine Residency Program
Florida State Univ. Medical School, Lee Memorial Health System Program
2014 Distinguished Fellow
American College of Cardiology
2011 Founder's Award
American College of Cardiology, Florida Chapter
2011 Golden Heart Award
American Heart Association, Southwest Florida Affiliate
2006 Distinguished Service Award
American College of Cardiology, Florida Chapter

Awards/Honors continued:

- 1998 Presidential Citation,
American College of Cardiology, Florida Chapter
- 1997 & 1994 Special Achievement Award
American College of Cardiology, Florida Chapter
- 1977 Omicron Delta Kappa Honorary
University of South Florida
- 1976 Alpha Omega Alpha, Medical Honorary
University South Florida College of Medicine

Publications:

1. Gilliam M, Westenbarger T, Hayes V, Lassell J, Chazal R. Efficacy and Safety of an Outpatient Parenteral Diuresis Program: Rapid Diuresis. *J Am Coll Cardiol*. 2022;79(9):376. doi:10.1016/s0735-1097(22)01367-5
2. Min, J., Chang, H., Andreini, D., Pontone, G., Guglielmo, M., Bax, J., Knaapen, P., Raman, S., Chazal, R., Freeman, A., Crabtree, T. and Earls, J. Coronary CTA plaque volume severity stages according to invasive coronary angiography and FFR. *J Cardiovasc Comput Tomogr*. 2022. doi:10.1016/j.jcct.2022.03.001
3. Chazal RA, Valentine CM. Cancer Patient Risk After Coronary Intervention: Words of Caution in Complicated Patients. *JACC Cardiovasc Interv*. 2021 Aug 23;14(16):1848. doi: 10.1016/j.jcin.2021.06.022. PMID: 34412803.
4. Benjamin IJ, Valentine CM, Oetgen WJ, Sheehan KA, Brindis RG, Roach WH Jr, Harrington RA, Levine GN, Redberg RF, Broccolo BM, Hernandez AF, Douglas PS, Piña IL, Benjamin EJ, Coylewright MJ, Saucedo JF, Ferdinand KC, Hayes SN, Poppas A, Furie KL, Mehta LS, Erwin JP 3rd, Mieres JH, Murphy DJ Jr, Weissman G, West CP, Lawrence WE Jr, Masoudi FA, Jones CP, Matlock DD, Miller JE, Spertus JA, Todman L, Biga C, Chazal RA, Creager MA, Fry ET, Mack MJ, Yancy CW, Anderson RE. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. *J Am Coll Cardiol*. 2021;77:3079-133 <https://pubmed.ncbi.nlm.nih.gov/33994057>
5. Chandrashekhar Y, Narula J, Chazal RA, et al. Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries. *Circulation*, June 2020, 141:2004–2025. DOI: 10.1161/CIRCULATIONAHA.119.041297
6. Escárcega RO, Bailey D, Chazal RA, Challenges for the Cardiovascular Community During the COVID-19 Pandemic. *Journal of the American College of Cardiology*, May 2020, <https://www.acc.org/latest-in-cardiology/features/accs-coronavirus-disease-2019-covid-19-hub#sort=%40commonsorthdate90022%20descending>
7. Goswami K, Chazal RA, *Cardiology update 2018: Cardiological Society of India*. New Delhi: Jaypee Brothers Medical. 217-220. 2019.
8. Chazal RA, RESPONSE: Dealing with Multiple Certifications and Recertifications. *Journal of the American College of Cardiology*, Mar 2019, 73 (11) 1360-1361; DOI: 10.1016/j.jacc.2019.02.028
9. Douglas PS, Biga C, Burns KM, Chazal RA, Cuffe MS, Daniel JM, Garzio C, Harrington RA, Patel HN, Walsh MN, Wolk MJ, 2019 ACC Health Policy Statement on Cardiologist Compensation and Opportunity Equity Writing Committee, *Journal of the American College of Cardiology*, Sep 2019, 26463; DOI:10.1016/j.jacc.2019.07.040
10. Valentine CM, Chazal RA, Oetgen WJ, ABIM Maintenance of Certification. *Journal of the American College of Cardiology*, Jun 2018, 24996; DOI: 10.1016/j.jacc.2018.05.020
11. Seals AA, Chazal RA, Promoting Initiatives in Quality of Cardiovascular Care. *Journal of the American College of Cardiology*, Jan 2017, 23309; DOI: 10.1016/j.jacc.2017.01.003

Publications continued:

12. Chazal RA, National Election Results: The Potential Impact on the ACC, Its Members, and Our Patients, Journal of the American College of Cardiology, Feb 2017, 69 (5) 592-593; DOI: 10.1016/j.jacc.2017.01.001
13. Chazal RA, Montgomery MJ, The Dyad Model and Value-Based Care. Journal of the American College of Cardiology, Mar 2017, 69 (10) 1353-1354; DOI: 10.1016/j.jacc.2017.02.007
14. Chazal RA, Recognizing Inevitable Change and Responding Responsibly. Journal of the American College of Cardiology, Mar 2017, 69 (12) 1637-1639; DOI: 10.1016/j.jacc.2017.02.019
15. Williams K, Sr., Chazal RA, Diversifying Our Ranks: A Call to Action. Journal of the American College of Cardiology, 2016; Vol. 67, No. 5: 588-589.
16. Chazal RA, China May Hold Answers to Addressing Cardiovascular Disease Epidemic. Journal of Translational Internal Medicine 2016; Vol. 4: 11-13.
17. Chazal RA, Creager MA, New Quality Measure Core Sets Provide Continuity for Measuring Quality Improvement: Concerns Raised About Conflicting BP Measures. Journal of the American College of Cardiology, 2016; Vol. 67, No.12: 1497-1498.
18. Chazal RA, A Call to Action in Changing Times. Journal of the American College of Cardiology, 2016; Vol. 67, No. 18: 2183-2185.
19. Chazal RA, ABIM Maintenance of Certification: Current Status. Journal of the American College of Cardiology, 2016; Vol. 67, No. 21: 2547-2549.
20. Chazal RA, Reading the Tea Leaves: Where Will Cardiology Be in 2050? Journal of the American College of Cardiology, 2016; Vol. 68 No. 2: 227-230.
21. Chazal RA, Poppas A. Governance Transformation: On the Path Toward a More Nimble, Strategic College. Journal of the American College of Cardiology, 2016; Vol. 68, No. 7: 763-765.
22. Antman EM, Bax J, Chazal RA, et al. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. Journal of the American College of Cardiology, 2016; Vol. 68, No. 13: 1474-1475.
23. Chazal RA, Casale PN, Martin GR, Preparing for a Value-Based Health Care System. Journal of the American College of Cardiology, 2016; Vol. 68, No. 15: 1698-1700.
24. Chazal RA, The Next “Chapter” in the ACC’s Chapter System. Journal of the American College of Cardiology, 2016; Vol. 68, No. 20: 2229-2231.
25. Chazal RA, Steven Houser, The ACC and AHA: Setting a New Standard for Hospital Accreditation-Together. Journal of the American College of Cardiology Dec 2016, 68 (24) 2708-2709; DOI: 10.1016/j.jacc.2016.10.027
26. Chazal RA, How New Technology Makes Heart Care Just a Beat Away. The Latest Technologies are Changing Monitoring and Treatment for Heart Health, Dec 2016
<http://www.futureofpersonalhealth.com/prevention-and-treatment/how-new-technology-makes-heart-care-just-a-beat-away>
27. Nallamathu B, Spertus J, Lansky A, et al:
Comparison of Clinical Interpretation with Visual Assessment and Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Contemporary Practice; The Assessing Angiography (A2) Project
Circulation, 127:1793-1800, 2013

Publications continued:

28. Harold J, O’Gara P, Chazal R, President’s Page: ACC Strategic Planning to Improve Value for Patients and Members Journal of the American College of Cardiology, Vol. 62, No. 1, 2013 July 2, 2013:82–3
29. Chazal RA, Valentine M: Cardiology Integration: Challenge and Opportunity Journal of the American College of Cardiology, Vol. 57, No. 21, 2011 ISSN 0735-1097/Doi:10.1016/j.jacc.2011.02.021
30. Dove JT, Brush, Jr JE, Chazal RA, Oetgen WJ: Medical Professional Liability and Health Care System Reform Journal of the American College of Cardiology, 55: 801-2803, 2010
31. Chazal RA, Tober R, Membrino G, Eberly Jr. A, Baker S: Patient Identification and Bystander-Initiated Actions in Acute Myocardial Ischemia. Journal of Florida Medical Association, 82:92-99, 1995.
32. McIntosh HD, Chazal RA, Alagona Jr. P, Doty WD: Early Management of Acute Myocardial Ischemic Events. Journal of Florida Medical Association, 82:143-145, 1995.
33. West SR, Sidell PM, Chazal RA: Detection of Right Atrial Thromboembolism by Two-Dimensional Echocardiography. Journal of Florida Medical Association, 74:676-679, 1987.
34. Chazal RA, Feigenbaum H: Two-Dimensional Echocardiographic Identification of Epicardial Pacemaker Wire Perforation. American Heart Journal, 107:165-167, 1984.
35. Chazal RA, Armstrong WF, Dillon JC, Feigenbaum H: Diastolic Ventricular Septal Motion in Atrial Septal Defect: Analysis of M-Mode Echocardiograms in 31 patients. American Journal of Cardiology, 52:1088-1090, 1983.
36. Altus P, Blanco R, Chazal RA: Trichinosis Masquerading as a Penicillin Allergy. JAMA, 243:767-768, 1980. Feb.

Abstracts:

1. Chazal RA, Armstrong WA, Fineberg NS, Green D, Dillon JC, Feigenbaum H: Critical Evaluation of Left Ventricular Minor Axis Dimensions Using Two-Dimensional Echocardiography: Reproducibility and Relationship to M-Mode Measurements. Clin Res, 31:174A, 1983.
2. Armstrong WF, Mueller TM, Chazal RA, Dillon JC, Feigenbaum H: Detection of Partial Coronary Occlusions with Computer Assisted Analysis of Contrast Enhanced Echocardiogram. J Am Coll Cardiol, 1 (2):645, 1983.

Recent Presentations:

<u>2022</u>		
Date	Location	Additional Information
February 18	ACC 2022 Cardiovascular Summit	Mini Intensive: The Advanced Cardiovascular Service Line Session
February 19	ACC 2022 Cardiovascular Summit	Advanced Negotiation: Co-Management/Job Offer Contracting/Employment Session
<u>2021</u>		
Date	Location	Additional Information
April 14	Florida Chapter – ACC Orlando	Early, Mid or Late Career: What Practices and Individuals Need to Consider for Retirement
April 27	Indiana University Zoom Mtg.	Grand Rounds
August 26	Employee Health Webex Mgt.	HeartHealth Program
<u>2020</u>		
February 6 – 9	Cardiovascular Summit, Washington DC	Novel Approaches for Access: Clinics/ Curbside Clinics/ Virtual/Telehealth I Am Burned Out on Burn Out: How Do I Fix That
<u>2019</u>		
Date	Location	Additional Information
February 14 – 16	CV Summit, Orlando, FL	Advanced Strategic Planning, Everything You Wanted to Know About Conflict of Interest, Time Management: Tricks for the Physician Leader
June 5 – 8	Cardiology Napa Valley 2019	Diagnostic and Prognostic Imaging, Genetics and Therapy (MODERATOR) MOC and My Certification (MODERATOR) Hypertension Guidelines Chest Pain Centers
July 18 – 19	8th Annual Cardiovascular Update	MOC: What is the Current Status
Sept. 20 – 22	10th Annual Cardiology Update, Newport Beach, CA	Review of the fourth universal definition of myocardial infarction and appropriate use of troponin testing
December 4 – 9	Cardiac Society of India, Delhi	ACC/AHA guidelines for heart failure management
<u>2018</u>		
January 25 - 28	Leadership Forum, ACC, Washington, DC	Leadership During Time of Change
February 22 – 24	ACC Summit, Las Vegas, NV	How to Create the Perfect Physician Schedule
Feb. 28 - March 4	Saudi Heart Association, Riyadh	Clinical Practice Guidelines in Heart Failure: Heart Failure with Preserved Ventricular Function Echo Assessments of RV
March 8 – 12	ACC 2018, Orlando, FL	Moving from the Triple Aim to the Quadruple Aim
April 3 – 4	Mount Sinai Grand Rounds, New York, NY	Grand Rounds: Triage of Chest Pain Patients in the ER

May 1 – 5	ARCA Italian Meeting, Catania, Italy	Heart Failure with Preserved Ventricular Function Echo Assessments of RV
May 30 – June 2	Argentine Federation of Cardiology, Mendoza	Chest Pain Explanation in the Emergency Room
June 6 – 9	Napa Valley Cardiology Conference 2018	Public Reporting: Carrot or Stick Hot Topics in Cardiology (Moderator) ABIM MOC ACC Welcome Consumer Driven Healthcare (Moderator)
Sept. 12 – 15	Brazilian Congress, Brasilia	Update on Valvular Heart Disease Manage this Patient
Sept. 23 – 29	Global Cardio-Oncology Summit, Tampa FL	Developing a Cardio-Oncology Program in the Community
October 26 – 27	ACC Ohio Chapter, Columbus	Issues from the ACC: What Is Impacting CV Providers in 2018
Nov. 18 – 24	70 th Annual Conference of the Cardiological Society of India, Mumbai	Encounter with the Chest Pain Patients in the ER Echocardiographic Assessment of RV Function

2017

Date	Location	Additional Information
March 9 – 14	Saudi Heart Association, Riyadh	Cardiology in the Next 50 Years Use of Chest Pain Centers to Improve Care
April 7 – 8	West Virginia Chapter Meeting	Issues from the ACC: A Town Hall with the Immediate Past President
April 27 – 30	XXVI Congress of Peru Society of Cardiology	Cardiology in the next 50 Years
May 6 – 7	WI Chapter Meeting, Lake Geneva, WI	Update from ACC National
July 10 – 15	Asian Pacific Society of Cardiology, Singapore	Top Three Leadership Tips Interventional Updates from ACC.17
July 20 – 21	Sixth Annual Chicago CV Update Meeting	Updates from the ACC
August 17	UF Health Shands Hospital, Gainesville, FL	Grand Rounds: Important Non-Clinical Cardiology Issues: An ACC Update
October 11 – 14	GWICC Conference, Beijing, China	Use of Chest Pain Centers
October 20 – 21	Indiana Chapter Meeting, Indianapolis, IN	What Is Impacting CV Providers in 2017
November 2 – 6	Brazilian Congress of Cardiology, Sao Paulo	Use of Radial Artery Access for Cath/PCI Managing Acute Heart Failure in 2017: An ACC Guideline
Nov. 28 – 29	Indiana University, Krannert Institute	Grand Rounds: ACC and the Krannert

Dec. 8 – 10	Colorado Chapter ACC, Colorado Springs, CO	National ACC Update
Dec. 14 – 17	Italian Society of Cardiology Meeting, Rome, Italy	Heart Failure Within Preserved EF
2016		
January 20	Brookings Roundtable, DC	APMs for Patients with CV Conditions
Jan. 26 – Feb. 1	India Annual Congress (APICON) Hyderabad	Chest Pain Protocols
Feb. 18 – 20	CV Summit, Las Vegas	CPC Effective Solutions
Feb. 23 – 24	Cape Coral Hospital's Rapid Diuresis Unit, FL	HF Education for Staff
March 8	University of South Florida	Grand rounds: Changes in Cardiovascular Care Implication for Cardiology
March 11 – 13	Mexican Society of Cardiology, Mexico City	
March 16 – 20	Japanese Circulation Society, Sendai	Symposium: Progress in the Treatment of Structural Heart Diseases
April 10 – 13	Annual Conference - Israel Heart Society, Tel Aviv	Use of Chest Pain Centers to Improve Patient Care Guideline Adherence and System Efficiency
April 14 - 17	Havana ACC Meeting, Havana, Cuba	Chest Pain Center
May 3 – 8	ARCA – Italy	Use of Guideline Based Protocols for Chest Pain Evaluation
May 12 – 16	Singapore Cardiac Society 28 th Annual	Symposium on Conquering Angina
June 6 – 10	British Cardiovascular Society, Manchester	Current ACC/AHA Lipid Guidelines: Time for a change
April 14 - 17	Havana ACC Meeting, Havana, Cuba	Chest Pain Center
Sept. 8 – 12	AACVPR, New Orleans	Team Based Care in the Era of MACRA: ACC Update
Sept. 30 – Oct. 2	Kansas Chapter Meeting, Overland Park	
October 6 – 7	Mt Sinai, NY	Future of Cardiology; In and Out of the Hospital
October 7 – 8	Texas Chapter Meeting, San Antonio	Update on the Biggest Issues Affecting US Cardiologists and ACC in 2016
October 11 – 15	GWICC 2016, Beijing	
October 19 – 20	Rhode Island Chapter Meeting, Providence	MACRA and Beyond
November 4 – 5	Washington Chapter Meeting, Seattle	MACRA
Nov. 17 – 19	Georgia Chapter Meeting, Greensboro	ACC Update

December 9 – 11	NY CV Summit, NYC	Update from the ACC
<u>2015</u>		
April 10 - 11	12th Annual Ponte Vedra CV Symposium	ACC Update
April 27 – 30	Asian Pac Soc of Cardiology, Abu Dhabi	Heart Failure with Preserved EF
May 1 – 3	ACC/Puerto Rico Chapter, San Juan	ACC Update
May 29 – 30	Alabama Chapter Mtg,	ACC Update
June 6 – 7	Oregon ACC CV Symposium, Portland	ACC’s Exciting Future
Sept. 8 – 12	Chinese Society of Cardiology, Shanghai	CSC and ACC: What We Can Learn Together to Improve Patient Care
Sept. 18 – 21	Brazilian Society of Cardiology, Sao Paulo	ACC Cardiovascular Prevention Experience
October 10	Colorado Chapter, Colorado Springs	“Top Ten” Topics ACC CV Summit
Oct. 21 – 27	Spanish Society of Cardiology, Bilbao	The Use of Chest Pain Centers and Protocols to Improve Care
Nov. 21 – 23	Mexican Society of Cardiology, Acapulco	HFpEF Presentation

Research Experience:

1. Principal Investigator, A Study Investigating Safety and Duration of Effect of an Oral Agent in a Controlled-Release Formulation in Patients with Stable Effort Angina Pectoris.
2. Sub-Investigator, The Safety and Efficacy of an Oral Agent in the Treatment of Stable Angina Pectoris.
3. Sub-Investigator, A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Fixed Low Doses of a Combination Oral Agent to Aspirin Alone in the Prevention of Reinfarction, Cardiovascular Death, and Stroke in Post-Myocardial Infarction Patients.
4. Sub-Investigator, An Open-Label Study of an Oral Agent in the Treatment of Patients with Hypercholesterolemia in Clinical Practice Settings.
5. Sub-Investigator, A Randomized, Double-Blind, Dose-Titration, Parallel Group. Placebo-Controlled Study to Evaluate the Effect of an Oral Agent on Mortality and Morbidity in Patients with Severe Heart Failure.
6. Sub-Investigator, A Randomized, Double-Blind Efficacy and Safety Evaluation of an Intravenous Agent vs. Placebo for Reducing the Complications of Coronary Angioplasty.
7. Sub-Investigator, A Multi-Center, Double-Blind, Randomized, Parallel, Ace-Controlled Study to Investigate the Safety and Tolerability of an Oral Agent on Elderly Patients with Symptomatic Heart Failure.
8. Sub-Investigator, A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Intravenous Agent on Cardiac Outcomes in Patients Undergoing PTCA or Atherectomy due to Unstable Angina Pectoris or Following Acute Myocardial Infarction.

Research Experience continued:

9. Sub-Investigator, A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Chronic Administration of an Oral Agent in Heart Failure.
10. Sub-Investigator, The Effect of an Oral Agent on all Causes of Mortality in Comparison with Placebo in Patients with Chronic Heart Failure (NYAH Class II-IV) Treated for Approximately 3 Years.
11. Principal Investigator, A Phase II, Dose-Ranging Study of an Oral Agent in Patients with Unstable Angina/Non-Q-Wave Myocardial Infarction.
12. Sub-Investigator, A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of an Oral Agent on Survival in Patients with Congestive Heart Failure.
13. Sub-Investigator, A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Design Clinical Trial to Assess the Safety and Efficacy of Antiarrhythmic Agent for the Prophylactic Treatment of Symptomatic Atrial Fibrillation/Flutter and/or Symptomatic Paroxysmal Supraventricular Tachycardia.
14. Sub-Investigator, A Triple-Blind, Parallel Study to Investigate the Comparison of Oral Agents on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy.
15. Principal Investigator, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Forced Dose Titration study Comparing Oral Agents in Patients with Chronic Stable Angina. (Phase III)
16. Principal Investigator, A Multi-Center, Double-Blind, 4-Arm, Parallel Study to Evaluate the Efficacy and Safety of an Oral Agent in Two Doses in Patients with Hypercholesterolemia (Phase III) and extension
17. Principal Investigator, CHF Patient Compliance Study
18. Sub-Investigator, A Phase II, Randomized, Open-Label, Multicenter, International, Angiographic Trial of the Efficacy of an Intravenous Agent Compound with an Accelerated Agent in Acute Myocardial Infarction.
19. Sub-Investigator, A Phase III, Multicenter, Randomized, Two-Arm Comparison, Blinded Endpoint Evaluation of Dilatation vs. Ablation Revascularization Trial Targeting Restenosis.
20. Sub-Investigator, A Randomized, Double-Blind Evaluation of the Efficacy and Safety of an Intravenous Agent vs. Placebo for reducing Mortality and Myocardial (Re) Infarction in Patients with Unstable Angina or Non Q-Wave Myocardial Infarction.
21. Sub-Investigator, A Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Anti-Arrhythmic Agent in Patients with an Implantable Cardioverter Defibrillator for the Treatment of Ventricular Arrhythmia.
22. Sub-Investigator, Clinical Study for Drug Eluting Collar on a Standard Lead (Device)
23. Sub-Investigator, An Evaluation of the Safety and Efficacy of RF Powered Cardiac Ablation Systems for the Treatment of Supraventricular Arrhythmias (Device)
24. Sub-Investigator, The Evaluation of an Intravenous Agent at Electrophysiology Testing (Phase III)
25. Sub-Investigator, Performance Evaluation of ECG Parameters of an ECG Monitor in the Clinical Environment
26. Sub-Investigator, Clinical Investigation of an RV Lead in Defibrillator Implants” (Phase III)
27. Sub-Investigator, Performance Evaluation of a Central Station Monitor in the Clinical Environment
28. Sub-Investigator, Trial-Fibrillation Follow-up Investigation of Rhythm Management (Phase III)

Research Experience continued:

29. Sub-Investigator, Study of the Efficacy of Intense Nursing Follow-Up Education on Compliance of Lipid Disorders (Phase IV)
30. Sub-Investigator, A Multicenter, Double-Blind, Randomized, Parallel, Oral Agent Controlled Study to Evaluate the Effects of XXX on Mortality in Patients with Symptomatic Heart Failure (Phase III)
31. Sub-Investigator, A 54-Week Open Label Assessment of the Safety and Efficacy Profile of an Oral Agent as Compared to Fluvastatin, Lovastatin, Simvastatin, Pravastatin When Used to
32. Sub-Investigator, Optimally Control Primary Hypercholesterolemia (Type IIA) and Mixed Dyslipidemia (Type IIB) (Phase III B)
33. Sub-Investigator, A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of an Oral Agent on the Clinical Status of Patients with Advanced Chronic Heart Failure and the Pharmacokinetics of an Oral Agent (Phase III)
34. Sub-Investigator, Oral SR-Agent Atrial Fibrillation Trial (Phase III)
35. Sub-Investigator, Open Label Long-Term Study in Patients with Chronic Heart Failure, who Participated in Controlled Clinical Studies with an Oral Agent (Phase III)
36. Sub-Investigator, Controlled Onset Oral Agent Investigation of Cardiovascular Endpoints (Phase III)
37. Sub-Investigator, Atrial Fibrillation and Mode Switching Pacemaker Study (Device)
38. Sub-Investigator, An Oral-Agent Vs. Aspirin to Yield Maximum Protection from Ischemic Heart Events Post Acute Coronary Syndromes (Phase III)
39. Sub-Investigator, A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Design Clinical Trial To Assess the Efficacy and safety of Different Doses of an Oral Agent for the Prophylactic Treatment of Symptomatic Atrial Fibrillation/Flutter and a Symptomatic Paroxysmal Supraventricular Tachycardia (Phase III)
40. Sub-Investigator, A Multi-Center, Open-Label, Clinical Trial to Assess the Long-Term Safety of Oral Agent in Patients with Atrial Fibrillation/Flutter and/or Paroxysmal Supraventricular Tachycardia (Phase III)
41. Sub-Investigator, A Multi-Center, Open-Label, Clinical Trial to Assess the Long-Term Safety of an Oral Agent in Patients with Atrial Fibrillation/Flutter and/or Paroxysmal Supraventricular Tachycardia (Phase III)
42. Sub-Investigator, The Clinical Investigation of an XXX Model RV/SVC Lead Study (Device)
43. Sub-Investigator, Validation of Alternate Thromboplastin Source for Use in the XXX Microcoagulation System
44. Sub-Investigator, A Randomized, Open-Label, Active Controlled Multi-Center, Phase III Safety Study of Two Doses of XXX Administered as a Continuous Infusion in the Treatment of Decompensated Heart Failure (Phase III)
45. Sub-Investigator, Performance Evaluation of ECG Parameters of the XXX Vital Sign Monitor
46. Sub-Investigator, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Forced Dose Titration Study Comparing Oral Agents in Patients with Chronic Stable Angina (Phase II)
47. Sub-Investigator, A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of Weekly Oral Antibiotic on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to *C. Pneumoniae*.

Research Experience continued:

48. Sub-Investigator, A Multicenter, Double-Blind, 4-Arm, Parallel Study to Evaluate the Efficacy and Safety of an Oral Agent in Two Doses in Patients with Hypercholesterolemia (Phase III)
49. Sub-Investigator, A Multicenter, Double-Blind, Three-Arm, Parallel Study to Evaluate the Long-Term Efficacy and Tolerability of an Oral Agent in Hypercholesterolemic Patients (Blinded Extension: Weeks 24-48) (Phase III)
50. Sub-Investigator, The Effect of Sustained-Release Oral Agent on Mortality and Morbidity in Patients with Congestive Heart Failure (Phase III)
51. Sub-Investigator, The Clinical Investigation of the Model "X" ICD (Device)
52. Sub-Investigator, A Long Term, Open-Label, Multi-Center Trial of the Safety and Efficacy of an Oral Agent in Patients with Dyslipidemia (Phase III-IV)
53. Sub-Investigator, A Multicenter Six Week Randomized Open-Label Parallel Arm Study Comparing the Efficacy of a Once Daily Oral Hyperlipidemic Agent to Another Oral Hyperlipidemic Agent in Hypercholesterolemic Patients (Phase II-IV)
54. Sub-Investigator, A Multicenter, International, Randomized, Double-Blind, Aspirin-Controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with an Oral Platelet Glycoprotein
55. IIb/IIIa Receptor Antagonist, as Therapy for the Long Term Prevention of Secondary Vascular Events in Patients after an Acute Coronary Syndrome (Phase III)
56. Sub-Investigator, A Multicenter Double-blind, Randomized, Placebo Controlled Study of the Effect of Subcutaneous Parenteral Agent on Clinical Improvement in Patients with Chronic Heart Failure (Phase II/III)
57. Sub-Investigator, A Randomized Double-Blind, Multicenter Trial to Compare the Short-term and Long-Term Efficacy and Safety of Three Oral Agents in the Treatment of Subjects with Hypercholesterolemia
58. Sub- Investigator, An Open-label, Multinational, Multicentre, Extension Trial to Assess the Long-Term Safety and Efficacy of XXX in Subjects in the XXX Clinical Trial Program
59. Sub-Investigator, A Multinational, Multicenter, Double-Blind, Randomized Active Controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-Term Treatment with Two Oral Agents and Their Combination in High-Risk Patients after Myocardial Infarction (Phase III)
60. Sub-Investigator, An Oral Agent and Coronary Events Study Protocol (Phase III)
61. Sub-Investigator, The Use of Passive Acoustic Imaging for the Detection of Coronary Artery Disease (Device)
62. Sub-Investigator, Prevention of Restenosis with an Oral Agent and Its Outcomes: A Placebo-Controlled Trial (Phase III)
63. Sub-Investigator, The Use of Passive Acoustic Imaging for the Detection of Coronary Artery Disease (Device)
64. Sub-Investigator, A Double-Blind Efficacy and Safety Study of an Oral Agent in Addition to an Oral Agent in Subjects with Coronary Heart Disease or Multiple Risk Factors and with Primary Hypercholesterolemia not Controlled by a Starting Dose of an Oral Agent (Phase III)

Research Experience continued:

65. Sub-Investigator, A Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Weekly, Oral Agent on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to C. Pneumoniae (Phase III)
66. Sub-Investigator, Performance Evaluation of the XXX Recombinant Prothrombin Time (rPT) Assay (Device)
67. Sub-Investigator, A Prospective Randomized Double-Blind, Multi-Center Study Comparing the Effects of Aggressive Lipid Lowering with Moderate Lipid Lowering on the Reduction of the Total Duration of Myocardial Ischemia in the Elderly as Measured by Holter Monitoring by Comparing the Maximal Doses of Two Statins; Study Assessing Goals in the Elderly (Phase IIIB)
68. Sub-Investigator, Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor XXX Compared with Dose-Adjusted Oral Agent in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (Phase III)
69. Sub-Investigator, Performance Evaluation of the Low-Dose Volume Assay for Use in the Protime Microcoagulation System (Device)
70. Sub-Investigator, XXX or YYY Evaluation and Infection Therapy (Phase IV)
71. Sub-Investigator, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Oral, Dose-Defining, Efficacy and Safety Study of an Agent in Patients with Extracellular Volume Expansion Secondary to Congestive Heart Failure" (Phase II)
72. Sub-Investigator, A Single-Arm, Open-Label Study of an Oral Agent in Community-based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and Patients with Cardiovascular Disease (Phase IV)
73. Sub-Investigator, Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity" and Extension (Phase II)
74. Sub-Investigator, A Prospective, Open Label, Randomized Comparison of Two Treatment Regimens: An Oral Agent Versus Usual Care in Patients Being Treated for Mild to Moderate Hypertension Who Need to Switch Drug Therapy
75. Sub-Investigator, A Double-Blind, Randomized Comparator Study Comparing the Renal Effects of XXX vs XXX in Chronic Stable Renal Failure Subjects Undergoing Coronary Angiography/Interventions" (Phase IV)
76. Sub-Investigator, An Open-Label, Randomized, Multi-center, Phase IIIb, Parallel Group, Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents XXX and XXX with XXX in High Risk Subjects with Type IIa and IIb Hypercholesterolemia" (Phase IIIb)
77. Sub-Investigator, A Multi-Center, 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXXX and XXXX Doses of Oral XXX XXX in Patients with an Implantable Cardioverter Defibrillator for the Treatment of Ventricular Arrhythmia" (Phase III)
78. Sub-Investigator, A Multi-center, Six-Month Double-blind, Placebo-controlled, Parallel-group design clinical study to Assess the Efficacy and Safety of a Daily Oral Dose of 125 mg XXX for the Prophylactic Treatment of Atrial Fibrillation and An Open-label, Follow-up Clinical Phase to Assess the Long-Term Efficacy and Safety of a 125 mg Daily Oral Dose of XXX" (Phase III)

Research Experience continued:

79. Sub-Investigator, A Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose Comparative Study of the Efficacy, Tolerability and Safety of XXX in Subjects with Chronic Heart Failure, NYHA Class II/III” (Phase II)
80. Sub-Investigator, A Multi-center, Eight-week, Double-blind Assessment Comparing the Efficacy and Assessing the Safety of XXX at Starting Doses of 10 mg, 20 mg, 40 mg and 80 mg” (Hypercholesterolemia) (Phase IV)
81. Sub-Investigator, A Multicenter, Double-Blind, Double-Dummy, Placebo – and Active – Controlled Study of an Oral Agent in Cardiac Compromised Subjects” (Phase II)
82. Sub-Investigator, A 48-Week Open-Label, Non-Comparative, Multicentre, Phase IIIb Study To Evaluate The Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects with Fredrickson Type IIa and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolaemia
83. Sub- Investigator, A 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of XXX 20 mg and 40 mg with that of YYY 80 mg in Subjects with Acute Coronary Syndromes (Phase III)
84. Sub- Investigator, Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (NIH, HF-ACTION)
85. Sub-Investigator, Phase 3 multi-center, double-blind, randomized, parallel group evaluation of the fixed combination xxx/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on the occurrence of major cardiovascular events in subjects with coronary heart disease or risk equivalents (Phase III)
86. Sub- Investigator, Trial to Assess Chelation Therapy (NIH TACT)
87. Sub-Investigator, A Randomized, Double-Blind Placebo-Controlled, Parallel Group, Comparative Study of CS-866 in Patients with Established Atherosclerosis (Phase III)
88. Sub- Investigator, Atrial Fibrillation XXX Trial with YYY for Prevention of Vascular Events (Phase III)
89. Sub-Investigator, A Multi-center, Open-Label, Follow-Up Study to Assess the Long-Term Safety of 125 mg per day of Oral XXX in Patients with an Implantable Cardioverter Defibrillator (Phase III)
90. Sub- Investigator, XXX/YYY Combination Tablets in Primary Hypercholesterolemia (Phase III)
91. Sub-Investigator, An eight-week Randomized Double-blind Placebo-controlled Multicenter Trial to Evaluate the Effects of XXX on Myocardial Ischemia in Subjects with Coronary Artery Disease (Phase III)
92. Sub-Investigator, A Two-Stage, Prospective, Randomized, Double-Blind Study of the Effects of an Isomolar Contrast Medium and a Hyperosmolar Contrast Medium on Serum Creatinine Concentration in Subjects with Elevated Serum Creatinine Undergoing Coronary Angiography/Interventions (Phase IV)
93. Sub- Investigator, A Multicenter, Double-Blind, Double-Dummy, Placebo – and Active – Controlled Study of an Oral Agent in Cardiac Compromised Subjects (Phase II)
94. Sub- Investigator, A Multi-country, Randomized, Double-blind, Parallel Placebo-controlled Trial to Assess the Effect of an Oral Agent on Morbidity and Mortality, Signs and Symptoms, Quality of Life in Patients with Stable Congestive Heart Failure (Phase III)

Research Experience continued:

95. Sub- Investigator, XXX for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (Phase III)
96. Principal Investigator, Randomized, multinational, double-blind, placebo-controlled, two-arm parallel group trial of XXX 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors (Phase III)
97. Sub-Investigator, Randomized Evaluation of long-term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of XXX with open label YYY for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial
98. Sub-Investigator, Aggressive reduction of Inflammation Stops Events (ARISE)
99. Principal Investigator, Phase 3 multi-center, double-blind, randomized, parallel group evaluation of the fixed combination xxx/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on the occurrence of major cardiovascular events in subjects with coronary heart disease or risk equivalents
100. Principal Investigator, A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients with Hypercholesterolemia at High Risk for CHD
101. Sub-Investigator, The Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia: A Dose-Ranging Study (SEACOAST)
102. Principal Investigator, A multi-center, randomized, double-blind, parallel arm, 12 week study to evaluate the efficacy and safety of Ezetimibe 10 mg when added to Atorvastatin 10 mg vs. titration to atorvastatin 20mg and 40mg in elderly patients with hypercholesterolemia at high risk for CHD not at their AHA/ACC/NCEP ATP III LDL-C goal
103. Principal Investigator, Phase 3 multi-center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily, compared to atorvastatin alone, on the occurrence of major cardiovascular events in subjects with coronary heart disease or risk equivalents (Illuminate)
104. Principal Investigator, An observational safety follow- up trial of the occurrence of major cardiovascular events and all-cause mortality in subjects who participated in the selected Torcetrapib / Atorvastatin clinical trials
105. Sub Investigator, The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators (RIGHT)
106. Sub-Investigator, ICD: AF Suppression Pacing to Prevent First Episode of Atrial Fibrillation in High Risk patients with an Implantable Cardioverter Defibrillator (Aspen – ICD)
107. Sub-Investigator, Long term multi-center extension of dabigatran treatment in patients with Atrial Fibrillation (RELY-ABLE)
108. Sub-Investigator, A randomized Double Blind trial comparing Oral Agent versus ASA to prevent Stroke in Atrial Fibrillation patients who have failed or are unsuitable for Vitamin K Antagonist Treatment (AVERROES)

Research Experience continued:

109. Sub-Investigator, Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and safety of Oral Agent at 50,100. or 300 mg OD with Amiodarone as a calibrator for the Prevention of ICD Interventions of Death (ALPHEE)
110. Principal Investigator, A multicenter, randomized, double-blind, parallel group active-controlled study to evaluate the efficacy and safety of Oral Agent compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction (Paradigm-HF)
111. Sub-Investigator, A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to assess the effects of Multaq® 400 mg BID for 12 weeks on Atrial Fibrillation Burden in Subjects with permanent pacemakers (Hestia)
112. Principal Investigator, Bridging Anticoagulation in patients who require temporary interruption of Warfarin Therapy for an elective invasive procedure or surgery (Bridge)